a Molecular Oncology Unit, Department of Biological Chemistry , Medical School, National and Kapodistrian University of Athens , Athens , Greece.
Expert Opin Investig Drugs. 2018 Jul;27(7):569-572. doi: 10.1080/13543784.2018.1494724. Epub 2018 Jul 6.
In the last years, a remarkable progress has been made in the clinical application of novel immunotherapy agents, the so called 'checkpoint inhibitors,' that has revolutionized the treatment of many malignant tumors. Their design has been based on the immune-mediated mechanisms of antitumor activity circle, such as antigen release and presentation, activation and trafficking of T-cells into tumors, depletion of immunosuppression, and immunogenic cell death. Various combinations of checkpoint inhibitors are being designed and/or tested, such as double checkpoint blockade, combination with chemotherapy, radiotherapy, molecularly targeted agents, and other immune-directed strategies.
在过去的几年中，新型免疫治疗药物（所谓的“检查点抑制剂”）在临床应用方面取得了显著进展，这一进展彻底改变了许多恶性肿瘤的治疗方式。这些药物的设计基于肿瘤杀伤免疫循环中的免疫介导机制，例如抗原释放和呈递、T 细胞向肿瘤内的激活和运输、免疫抑制的耗竭以及免疫原性细胞死亡等。目前正在设计和/或测试各种检查点抑制剂的组合，例如双重检查点阻断、与化疗、放疗、分子靶向药物和其他免疫导向策略联合应用等。
